-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Short Interest in Amarin Co. Plc (NASDAQ:AMRN) Drops By 9.0%
Short Interest in Amarin Co. Plc (NASDAQ:AMRN) Drops By 9.0%
Amarin Co. plc (NASDAQ:AMRN – Get Rating) was the target of a significant decrease in short interest in the month of August. As of August 31st, there was short interest totalling 12,720,000 shares, a decrease of 9.0% from the August 15th total of 13,980,000 shares. Based on an average daily trading volume, of 3,760,000 shares, the short-interest ratio is presently 3.4 days.
Institutional Investors Weigh In On Amarin
Institutional investors have recently modified their holdings of the stock. Creative Planning grew its stake in Amarin by 66.4% in the second quarter. Creative Planning now owns 17,285 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 6,900 shares in the last quarter. Quantbot Technologies LP acquired a new position in Amarin in the first quarter worth about $31,000. Winthrop Advisory Group LLC acquired a new position in Amarin in the first quarter worth about $34,000. Kalos Management Inc. acquired a new position in Amarin in the first quarter worth about $37,000. Finally, Advisor Resource Council acquired a new position in Amarin in the second quarter worth about $37,000. Institutional investors and hedge funds own 34.15% of the company's stock.
Get Amarin alerts:Wall Street Analysts Forecast Growth
Separately, StockNews.com raised shares of Amarin from a "sell" rating to a "hold" rating in a research note on Wednesday, July 27th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $2.50.
Amarin Trading Down 4.3 %
AMRN opened at $1.10 on Thursday. The company has a fifty day simple moving average of $1.34 and a 200 day simple moving average of $1.97. The firm has a market cap of $443.53 million, a price-to-earnings ratio of -4.40 and a beta of 1.87. Amarin has a twelve month low of $1.09 and a twelve month high of $5.52.Amarin (NASDAQ:AMRN – Get Rating) last released its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.05). The firm had revenue of $94.44 million for the quarter, compared to analyst estimates of $88.21 million. Amarin had a negative net margin of 21.05% and a negative return on equity of 13.63%. Amarin's revenue for the quarter was down 38.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.02 earnings per share. On average, analysts forecast that Amarin will post -0.36 earnings per share for the current fiscal year.
About Amarin
(Get Rating)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Featured Stories
- Get a free copy of the StockNews.com research report on Amarin (AMRN)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.
Amarin Co. plc (NASDAQ:AMRN – Get Rating) was the target of a significant decrease in short interest in the month of August. As of August 31st, there was short interest totalling 12,720,000 shares, a decrease of 9.0% from the August 15th total of 13,980,000 shares. Based on an average daily trading volume, of 3,760,000 shares, the short-interest ratio is presently 3.4 days.
愛馬林股份有限公司(納斯達克:AMRN-GET評級)是空頭股數8月份大幅下降的目標。截至8月31日,空頭股數共有1272萬股,比8月15日的1398萬股減少了9.0%。以日均成交量3,760,000股計算,目前短息比率為3.4天。
Institutional Investors Weigh In On Amarin
機構投資者看好Amarin
Institutional investors have recently modified their holdings of the stock. Creative Planning grew its stake in Amarin by 66.4% in the second quarter. Creative Planning now owns 17,285 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 6,900 shares in the last quarter. Quantbot Technologies LP acquired a new position in Amarin in the first quarter worth about $31,000. Winthrop Advisory Group LLC acquired a new position in Amarin in the first quarter worth about $34,000. Kalos Management Inc. acquired a new position in Amarin in the first quarter worth about $37,000. Finally, Advisor Resource Council acquired a new position in Amarin in the second quarter worth about $37,000. Institutional investors and hedge funds own 34.15% of the company's stock.
機構投資者最近調整了對該股的持有量。創意策劃在第二季度增持了66.4%的Amarin股份。在上個季度又購買了6900股後,Creative Planning現在擁有這家生物製藥公司17,285股股票,價值26,000美元。Quantbot Technologies LP在第一季度收購了Amarin的一個新頭寸,價值約3.1萬美元。温斯羅普諮詢集團有限責任公司在第一季度收購了阿馬林的一個新頭寸,價值約3.4萬美元。今年第一季度,Kalos Management Inc.收購了阿馬林的一個新頭寸,價值約3.7萬美元。最後,顧問資源委員會在第二季度在阿馬林獲得了一個價值約3.7萬美元的新職位。機構投資者和對衝基金持有該公司34.15%的股票。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
Separately, StockNews.com raised shares of Amarin from a "sell" rating to a "hold" rating in a research note on Wednesday, July 27th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $2.50.
另外,在7月27日星期三的一份研究報告中,StockNews.com將Amarin的股票評級從賣出上調至持有。兩名投資分析師對該股的評級為賣出,四名分析師給予該股持有評級,一名分析師給予該股買入評級。根據MarketBeat.com的數據,該股目前的平均評級為持有,平均目標價為2.50美元。
Amarin Trading Down 4.3 %
Amarin股價下跌4.3%
Amarin (NASDAQ:AMRN – Get Rating) last released its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.05). The firm had revenue of $94.44 million for the quarter, compared to analyst estimates of $88.21 million. Amarin had a negative net margin of 21.05% and a negative return on equity of 13.63%. Amarin's revenue for the quarter was down 38.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.02 earnings per share. On average, analysts forecast that Amarin will post -0.36 earnings per share for the current fiscal year.
愛馬林(納斯達克代碼:AMRN-GET Rating)最近一次發佈季度收益報告是在8月3日星期三。這家生物製藥公司公佈的季度每股收益為0.11美元,低於分析師普遍預期的0.06美元和0.05美元。該公司本季度營收為9444萬美元,而分析師預期為8821萬美元。Amarin的淨利潤率為負21.05%,股本回報率為負13.63%。Amarin本季度的收入同比下降了38.9%。去年同期,該業務公佈的每股收益為0.02美元。分析師平均預測,Amarin本財年的每股收益將為0.36美元。
About Amarin
關於阿瑪林
(Get Rating)
(獲取評級)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Amarin Corporation plc是一家制藥公司,在美國、德國、加拿大、黎巴嫩和阿拉伯聯合酋長國從事心血管疾病治療藥物的開發和商業化。它的主要產品是Vascepa,一種僅限處方的omega-3脂肪酸產品,用作飲食的輔助產品,用於降低患有嚴重高甘油三酯血癥的成年患者的甘油三酯水平。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Amarin (AMRN)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
- 免費獲取StockNews.com關於Amarin的研究報告(Amrn)
- 對塔吉特來説,最糟糕的時期可能已經過去,但這隻股票買起來安全嗎?
- 這些液態天然氣股票準備好上行了嗎?
- 內部人士正在買入的兩隻有趣的股票
- 諾華在避險市場中仍是一隻冒險的股票
- 連續60年提高股息的3只防御性股票
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.
接受《阿馬林日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Amarin和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧